(Q39573304)
Statements
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts (English)
Marie-Christine Etienne-Grimaldi
Jean-Louis Fischel
Anne Sudaka
Nicolas Toussan
Patricia Formento
Gérard Milano
21 March 2011